Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response.

Nilubol N, Boufraqech M, Zhang L, Gaskins K, Shen M, Zhang YQ, Gara SK, Austin CP, Kebebew E.

Oncotarget. 2018 Aug 31;9(68):33030-33042. doi: 10.18632/oncotarget.26050. eCollection 2018 Aug 31.

2.

Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo.

Thakur S, Daley B, Gaskins K, Vasko VV, Boufraqech M, Patel D, Sourbier C, Reece J, Cheng SY, Kebebew E, Agarwal S, Klubo-Gwiezdzinska J.

Clin Cancer Res. 2018 Aug 15;24(16):4030-4043. doi: 10.1158/1078-0432.CCR-17-3167. Epub 2018 Apr 24.

3.

Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors.

Nilubol N, Yuan Z, Paciotti GF, Tamarkin L, Sanchez C, Gaskins K, Freedman EM, Cao S, Zhao J, Kingston DGI, Libutti SK, Kebebew E.

J Natl Cancer Inst. 2018 Sep 1;110(9):1019-1029. doi: 10.1093/jnci/djy003.

4.

Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.

Kotian S, Zhang L, Boufraqech M, Gaskins K, Gara SK, Quezado M, Nilubol N, Kebebew E.

Clin Cancer Res. 2017 Sep 1;23(17):5044-5054. doi: 10.1158/1078-0432.CCR-17-1043. Epub 2017 Jun 9.

5.

RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.

Liu-Chittenden Y, Jain M, Gaskins K, Wang S, Merino MJ, Kotian S, Kumar Gara S, Davis S, Zhang L, Kebebew E.

Oncogene. 2017 Jun 22;36(25):3541-3552. doi: 10.1038/onc.2016.497. Epub 2017 Jan 23.

6.

Serum RARRES2 Is a Prognostic Marker in Patients With Adrenocortical Carcinoma.

Liu-Chittenden Y, Patel D, Gaskins K, Giordano TJ, Assie G, Bertherat J, Kebebew E.

J Clin Endocrinol Metab. 2016 Sep;101(9):3345-52. doi: 10.1210/jc.2016-1781. Epub 2016 Jun 23.

7.

Efficacy and safety of insulin lispro in obese patients with type 2 diabetes: a retrospective metaanalysis of 7 randomized controlled trials.

Rees TM, Curtis BH, Gaskins KA, Sierra-Johnson J, Jiang HH, Liu R, Holcombe JH.

Endocr Pract. 2014 May;20(5):389-98. doi: 10.4158/EP13301.OR.

PMID:
24325997
8.

Patterns and trends in insulin intensification among patients with type 2 diabetes: a systematic review.

Polinski JM, Connolly JG, Curtis BH, Seeger JD, Gaskins K, Perez M, Smith BF, Shrank WH.

Prim Care Diabetes. 2014 Jul;8(2):101-9. doi: 10.1016/j.pcd.2013.10.008. Epub 2013 Nov 22. Review.

PMID:
24275103
9.

An in vivo mouse model of metastatic human thyroid cancer.

Zhang L, Gaskins K, Yu Z, Xiong Y, Merino MJ, Kebebew E.

Thyroid. 2014 Apr;24(4):695-704. doi: 10.1089/thy.2013.0149. Epub 2014 Mar 10.

10.

Efficacy and safety of insulin lispro in geriatric patients with type 2 diabetes: a retrospective analysis of seven randomized controlled clinical trials.

Curtis BH, Rees TM, Gaskins KA, Sierra-Johnson J, Liu R, Jiang HH, Holcombe JH.

Aging Clin Exp Res. 2014 Feb;26(1):77-88.

11.

Efficient, thermally stable, second order nonlinear optical response in organic hybrid covalent/ionic self-assembled films.

Heflin JR, Guzy MT, Neyman PJ, Gaskins KJ, Brands C, Wang Z, Gibson HW, Davis RM, Van Cott KE.

Langmuir. 2006 Jun 20;22(13):5723-7.

PMID:
16768500
12.

Electrolytes of breast-cyst fluid.

Gatzy JT, Zaytoun MP, Gaskins K, Pearlman WH.

Clin Chem. 1979 May;25(5):745-8.

Supplemental Content

Loading ...
Support Center